T Ohnoshi
- Hepatology top 10%
- Oncology top 10%
- Lung Cancer Research Studies 25
- Cancer Treatment and Pharmacology 9
- Cancer Diagnosis and Treatment 7
-
- Neuroendocrine Tumor Research Advances 17
-
- Lung Cancer Treatments and Mutations 18
-
- Cancer therapeutics and mechanisms 11
-
- Lymphoma Diagnosis and Treatment 11
-
- Sarcoidosis and Beryllium Toxicity Research 7
- Co-authors
- Hiroshi UeokaIkuro KimuraKatsuyuki KiuraBarton A. KamenJames F. HollandTakao OhnumaKevin J. ScanlonI Kimura
- Cited by
- HepatologyOncologyEpidemiology
- Partner nations
- JapanUnited StatesGreece
In The Last Decade
T Ohnoshi
82 papers receiving 677 citations
Peers
Comparison fields: 5 of 78
- Hepatology 111
- Oncology 308
- Epidemiology 200
- Pulmonary and Respiratory Medicine 159
- Hematology 54
Countries citing papers authored by T Ohnoshi
This map shows the geographic impact of T Ohnoshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T Ohnoshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T Ohnoshi more than expected).
Fields of papers citing papers by T Ohnoshi
This network shows the impact of papers produced by T Ohnoshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T Ohnoshi. The network helps show where T Ohnoshi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside T Ohnoshi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. | 2005 | 11 |
| 2 | Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. | 1998 | 20 |
| 3 | 1997 | 3 | |
| 4 | [Gingival metastasis of large-cell lung cancer that produced G-CSF]. | 1995 | 3 |
| 5 | 1994 | 2 | |
| 6 | 1993 | 10 | |
| 7 | 1993 | 2 | |
| 8 | 1992 | 23 | |
| 9 | 1991 | 3 | |
| 10 | 1991 | 5 | |
| 11 | 1991 | 22 | |
| 12 | 1990 | 0 | |
| 13 | 1990 | 7 | |
| 14 | [Pilot phase II study of hybrid chemotherapy of CAV-PVP in small cell lung cancer (SCLC)]. | 1989 | 1 |
| 15 | 1987 | 26 | |
| 16 | 1986 | 3 | |
| 17 | 1985 | 16 | |
| 18 | Spontaneous, complete remission in adult T-cell leukemia: a case report. | 1983 | 9 |
| 19 | [Phase I study of an oral administration of VP 16-213]. | 1983 | 1 |
| 20 | 1978 | 0 |
About T Ohnoshi
T Ohnoshi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 92 papers that have together received 721 indexed citations. Recurring topics across this work include Lung Cancer Research Studies (25 papers), Lung Cancer Treatments and Mutations (18 papers), Neuroendocrine Tumor Research Advances (17 papers), Cancer therapeutics and mechanisms (11 papers), Lymphoma Diagnosis and Treatment (11 papers), Cancer Treatment and Pharmacology (9 papers), Sarcoidosis and Beryllium Toxicity Research (7 papers) and Cancer Diagnosis and Treatment (7 papers). The work is most often cited by research in Hepatology (111 citations), Oncology (308 citations) and Epidemiology (200 citations). T Ohnoshi has collaborated with scholars based in Japan, United States and Greece. Frequent co-authors include Hiroshi Ueoka, Ikuro Kimura, Katsuyuki Kiura, Barton A. Kamen, James F. Holland, Takao Ohnuma, Kevin J. Scanlon, I Kimura, Nagio Takigawa and Takuo Shibayama. Their work appears in journals such as Lung Cancer, Japanese Journal of Clinical Oncology, Cancer, Cancer Immunology Immunotherapy and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.